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INTRODUCTION
Variceal bleeding is one of the life-threatening complica-
tions in patients with cirrhosis and reportedly accounted for
a 40-60% mortality rate in these patients 30 to 40 yr ago
(1-5). During recent decades, however, there has been sig-
nificant progress in and diversification of hemostatic modalities
for variceal bleeding, including pharmacologic, endoscopic,
surgical, and radiological therapies. Several recent studies
have suggested that mortality of patients with cirrhosis and
acute variceal bleeding has significantly decreased over the
past two decades (5-9). 
In addition to the improvement in initial hemostatic man-
agement, several other factors might play a role in improved
survival after variceal hemorrhage. Rebleeding may occur in
as high as 70% of patients with cirrhosis who experience a
variceal bleed and is associated with a very high mortality
(2). Currently recommended practice is secondary prophy-
laxis with a nonselective beta-blocker (10) and endoscopic
variceal eradication (11, 12) to prevent rebleeding and increase
the survival rate. Indeed, several recent studies have report-
ed that such secondary prevention considerably reduced the
incidence of rebleeding (5, 8, 9). Likewise, bacterial infection
is a common phenomenon after variceal bleeding in patients
with cirrhosis and appears to be associated with failure to
control bleeding as well as with septic complications (13).
Because bleeding might be provoked by microbial endotox-
ins, which increase portal pressure and prophylactic antibi-
otics reportedly substantially reduce mortality in patients
with variceal hemorrhage, antibiotic prophylaxis is now a
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Clinical Features and Treatment Outcomes of Upper Gastrointestinal
Bleeding in Patients with Cirrhosis
With recent progress in treatment modalities, mortality from upper gastrointestinal
(UGI) bleeding has decreased appreciably. The aim of this study was to establish
how UGI bleeds are managed in Korean patients with cirrhosis and to evaluate
treatment outcomes. A total of 479 episodes of acute UGI bleeding in 464 patients
with cirrhosis were included during a six-month period at nine tertiary medical cen-
ters. Treatment outcomes were assessed by failure to control bleeding, rebleeding
and mortality. The source of bleeding was esophagogastric varices in 77.7% of
patients, nonvariceal lesions in 15.9%, and undefined in 6.5%. For control of bleed-
ing, endoscopic and pharmacologic treatments were used in 74.7% and 81.9% of
patients, respectively. Variceal ligation was a major technique for endoscopic treat-
ment (90%), and terlipressin and somatostatin were the main pharmacologic agents
used (96.4%). Initial hemostasis was achieved in 86.8% of cases, but rebleeding
occurred in 3.8% and 16.8% of cases within five days and six weeks of hemorrhage,
respectively. Five-day and six-week mortality were 11.3% and 25.9%, respective-
ly. Survival of patients with variceal bleeding seems to be remarkably improved than
previous reports, which may suggest the advances in hemostatic methods for con-
trol of variceal hemorrhage.
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recommended practice on admission (14).
We previously reported improved survival in Korean pati-
ents with cirrhosis and variceal bleeding in a cohort within
a single institution (15). However, there has been no nation-
wide survey to assess the prognosis of upper gastrointestinal
(UGI) bleeding in cirrhotic patients and to assess whether
they are appropriately managed in accordance with general
standard guidelines for initial hemostasis, prevention of
rebleeding, and antibiotic prophylaxis. Therefore, we con-
ducted a multicenter cohort study to identify how UGI bleeds
are managed in Korean patients with cirrhosis and to iden-
tify treatment outcomes.
MATERIALS AND METHODS
Patients and data collection
This multicenter, retrospective study included a total of
479 episodes of acute UGI bleeding in 464 patients with
cirrhosis. Subjects were all patients with cirrhosis, consecu-
tively admitted for hematemesis and/or melena between May
and October 2005 at nine tertiary medical centers distribut-
ed throughout Korea. The medical records of enrolled patients
were reviewed to obtain necessary demographic, clinical, labo-
ratory, treatment, and follow-up data. Gender, age at diag-
nosis, etiology of cirrhosis, presence of ascites, portal vein
thrombosis, hepatocellular carcinoma, and laboratory results
at presentation (hemoglobin, leukocyte and platelet count,
albumin, bilirubin, aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase, hepatitis serological tests)
were also identified. Further identified from the medical
records were acute therapy for hemostasis, prophylactic thera-
py, and the amount of blood transfused. Diagnosis of cirrho-
sis was based on a previous liver biopsy or on compatible clini-
cal, laboratory and imaging findings. Source of bleeding was
classified with endoscopic findings as variceal (esophageal or
gastric varices), nonvariceal (portal hypertensive gastropathy;
esophageal, gastric or duodenal ulcers; Mallory-Weiss syn-
drome; sclerotherapy/banding-induced ulcerations), or unde-
fined (that is, unidentified source of bleeding or no endos-
copy). In addition, time intervals from start of bleeding to
hospital admission, from admission to endoscopy, and from
start of bleeding to endoscopy were reviewed. All patients
were followed up to the time of death or 42 days from admis-
sion. For patients who had multiple hospitalizations for UGI
bleeding during the study period, rebleeding after 42 days
of index bleed was considered as a new episode. The size of
esophageal varices was classified according to the criteria of
Beppu et al. (16). The classification of gastric varices was
based on criteria by Sarin et al. (17). The hepatic function of
patients at admission was graded according to the Child-Pugh
classification (4).
Definitions
The following definitions were based on recommendations
from the Baveno II, III and IV consensus workshops (14, 18,
19). 1) Time zero of the bleeding episode: the time of admis-
sion to the first hospital to which the patient was taken, 2)
source of bleeding: a lesion actively bleeding or with adher-
ent clot, white nipple, or presence of a single lesion without
other potential sources of bleeding, 3) type of bleeding: bleed-
ing was defined as active if a spurting or oozing lesion was
seen on endoscopy, or if fresh blood was regurgitated via the
gastric tube when endoscopy was not allowed, 4) control of
bleeding: the acute bleeding episode was considered finished
at the beginning of the first 24-hr interval with no hemateme-
sis, stable hemoglobin concentration without blood transfu-
sions, and stable hemodynamic conditions (absence of sys-
tolic blood pressure or reduction of 20 mmHg or more, and
increase of heart rate of 20/min or more), and 5) rebleeding:
any occurrence of hematemesis or hemoglobin drop with
fresh melena after initial control of bleeding.
Treatment outcomes were assessed in accordance with the
failure to control index bleeding, rebleeding and death
within 42 days from time 0 of index bleed. Five-day failure
was defined as failure to control bleeding, rebleeding, or
death within 5 days of admission. 
The presence of infectious diseases at admission and their
development during hospitalization were investigated with
appropriate diagnostic methods and cultures. Patients with
a fever >38℃ that lasted more than 24 hr and leukocytosis
with a shift to the left, but without any other evidence of infec-
tion, were considered as having ‘‘possible infections’’ (20).
Statistical analysis
Qualitative variables were expressed as percentages and
compared using Pearson’s chi-square test. Quantitative vari-
ables were expressed as mean±standard deviation and com-
pared using Student’s t-test. Cumulative rates of survival were
estimated by the Kaplan-Meier method and comparisons
between patient subgroups were made with the use of log-
rank tests. All tests were two-tailed, and p values below 0.05
were considered to indicate statistical significance. All the
statistical analyses were performed using SPSS version 10.0.
RESULTS
Characteristics of cohorts
Demographic, clinical, and laboratory data at admission
are presented in Table 1. In the whole series, 421 (87.9%)
out of 479 episodes of UGI bleeds occurred in males and the
mean age was 54.5 yr. Liver cirrhosis was related to heavy
alcohol intake in 43.4% of patients, to hepatitis B virus inUpper Gastrointestinal Bleeding in Cirrhosis 637
29%, to hepatitis C virus in 4.8%, and to both alcohol and
virus in 15.7%. The mean systolic blood pressure was 111
mmHg and the mean heart rate was 91/min. Hemoglobin
concentration averaged 10.5 g/dL. Ascites and hepatic ence-
phalopathy were found in 57.4% and 15.7% of patients,
respectively. According to the Child-Pugh classification, 86
(18%) patients were included in grade A, 203 (42.4%) in
grade B, and 190 (39.7%) in grade C. Portal vein thrombo-
sis and hepatocellular carcinoma were combined in 14.8%
and 32.4% of patients, respectively.
When included in this study, 220 (45.9%) patients had a
history of at least one episode of previous bleeding, mainly
caused by variceal rupture (185 of 220 cases, 84.1%), and
144 (77.8%) of them had received preventive measures against
rebleeding. In contrast, among 259 patients without previ-
ous bleeds, only 24 (9.3%) were receiving prophylaxes.
Source and type of bleeding
The median time from initial sign of bleeding to hospital
admission was 17 hr (range 0-96 hr) and from admission to
endoscopy was six hours (range 0-158 hr). Endoscopy revealed
the source of bleeding in 448 (93.5%) of 479 episodes as fol-
lows: esophageal varices in 273 patients (57%), gastric varices
in 99 (20.7%), gastric ulcer in 48 (10%), duodenal ulcer in
16 (3.3%), and other lesions in 12 (2.5%). The size of varices
*Mean±standard deviation; variceal, patients with variceal bleeding; nonvariceal, patients with bleeding from other sources than varices; undefined,
patients with bleeding from undefined sources. T0, the time of admission to the hospital to which the patient was taken; HBV, hepatitis B virus; HCV,
hepatitis C virus.
Source of bleeding
Variceal Non-variceal Undefined Total
Characteristics
No. patients 372 (77.7%) 76 (15.9%) 31 (6.5%) 479
Men/women 328/44 65/11 28/3 421/58
Age (yr)* 54.110.9 55.6±11.1 57.0±10.9 54.5±10.9
Etiology, n (%)
Alcohol abuse 162 (43.5) 32 (42.1) 14 (45.2) 208 (43.4) 
HBV 106 (28.5) 22 (28.9) 11 (35.5) 139 (29.0)
HCV 20 (5.4) 2 (2.6) 1 (3.2) 23 (4.8)
Virus+alcohol 55 (14.8) 15 (19.7) 5 (16.1) 75 (15.7)
Others 29 (7.8) 5 (6.6) 0 (0.0) 34 (7.1)
Hemoglobin (g/dL)* 11.0±37.7 8.8±2.4 9.1±2.4 10.5±33.3
BUN (mg/dL)* 30.8±21.7 44.9±113.6 38.3±24.5 33.5±49.4
Creatinine (mg/dL)* 1.2±1.2 1.4±1.4 2.2±1.2 1.3±1.3
Bilirubin (mg/dL)* 3.7±5.0 3.6±5.9 7.4±8.9 3.9±5.5
Albumin (g/dL)* 2.8±1.3 2.9±0.7 2.6±0.7 2.8±1.2
Prothrombin activity (%)* 57.1±27.9 61.8±19.2 45.1±18.0 57.1±26.4
Ascites, n (%)
Absent 158 (42.5) 37 (48.7) 9 (29.0) 204 (42.6)
Moderate 99 (26.6) 15 (19.7) 8 (25.8) 122 (25.5)
Severe 115 (30.9) 24 (31.6) 14 (45.2) 153 (31.9)
Encephalopathy, n (%)
Absent 326 (87.6) 67 (88.2) 11 (35.5) 404 (84.3)
Moderate 32 (8.6) 5 (6.6) 7 (22.6) 44 (9.2)
Severe 14 (3.8) 4 (5.3) 13 (41.9) 31 (6.5)
Child-Pugh class, n (%)
A 66 (17.7) 20 (26.3) 0 (0.0) 86 (18.0)
B 162 (43.5) 32 (42.1) 9 (29.0) 203 (42.4)
C 144 (38.7) 24 (31.6) 22 (71.0) 190 (39.7)
Child-Pugh score* 8.8±2.2 8.5±2.4 10.7±2.0 8.9±2.3
Portal vein thrombosis, n (%) 52 (14.0) 12 (15.8) 7 (22.6) 71 (14.8)
Hepatocellular carcinoma, n (%) 117 (31.5) 29 (38.2) 9 (29.0) 155 (32.4)
Systolic pressure (mmHg)* 112.0±23.3 112.9±22.2 90.0±27.3 110.7±24.0
Heart rate (beats/min)* 91.3±21.2 90.6±19.6 95.3±29.2 91.4±21.5
Time intervals (hr)
Start of bleeding to T0 14.6±31.2 21.6±34.3 6.4±15.7 15.2±31.1
T0 to endoscopy 12.0±26.6 25.8±64.6 - 14.3±36.2
Start of bleeding to endoscopy 27.7±44.3 41.6±48.5 - 30.2±45.3
Table 1. Demographic and clinical characteristics of the cohort on admission638 Y.S. Seo, Y.H. Kim, S.H. Ahn, et al.
in 273 patients who bled from esophageal varices was F1 in
16 patients (5.9%), F2 in 118 (43.2%), and F3 in 139 (50.9
%). Red color sign was noted in 243 patients (89%). The
types of gastric varices were GOV1 in 56 patients (56.6%),
GOV2 in 38 (38.4%), and IGV1 in 5 (5%). In 31 patients,
however, the source of bleeding remained undefined because
endoscopy was unsatisfactory. In one patient, it was due to
hemodynamic instability, and endoscopic evaluation could
not be performed in 30 patients for the following reasons:
massive bleeding with encephalopathy in six, massive bleed-
ing with hemodynamic instability in 21, and refusal of en-
doscopy in three. Active bleeding was found in 184 (38.4%)
of 479 episodes either by endoscopy or by gastric aspirate.
Among the patients with bleeding from identified sources,
there were no significant differences in type of bleeding accord-
ing to the source of bleeding (p=0.627). On the other hand,
the patient group who bled from undefined sources exhibit-
ed active bleedings in all cases and contained more patients
with encephalopathy and severe hepatic dysfunction, and
thus included in Child-Pugh grade C, as compared with
other groups (p<0.001).
Treatment
Types of treatments employed for initial hemostasis are
represented in Table 2. In the whole series, pharmacologic
treatments were performed in 81.9% of patients, endoscop-
ic treatment in 74.7%, and balloon tamponade in 10.9%.
In one case, a transjugular intrahepatic portosystemic shunt
was inserted. The treatment modalities were applied in com-
bination in most cases (69.3%) but alone in some cases. The
most frequent type of combination was pharmacologic plus
endoscopic treatment (287 cases, 59.9%). There were no sig-
nificant differences in types of treatment for initial hemosta-
sis between patients with HCC and portal vein invasion and
the others (p=0.374).
The pharmacologic agents used for initial hemostasis were
terlipressin in 42.4% of episodes, somatostatin in 35.5%,
and octreotide in 2.9%. They were administered in advance
of diagnostic endoscopy in 84.8% of cases. The median (range)
dose and duration of each drug was 4 (3-6) mg/day for 3 (1-8)
days for terlipressin, 6 (6) mg/day for 3 (1-8) days for somato-
statin, and 0.6 (0.6) mg/day for 4 (2-8) days for octreotide.
Endoscopic treatment for initial hemostasis was carried out
during initial diagnostic endoscopy in 252 of 310 patients
(81.3%), or otherwise on an elective basis and in stable hemo-
dynamic conditions at the median time of nine hours after
admission. The major endoscopic techniques for treating
variceal and nonvariceal hemorrhage were banding ligation
(279 of 310 patients, 90%) and electrocoagulation (20 of 48
patients, 41.7%), respectively. To control the bleeding from
esophageal varices, banding ligation and endoscopic injec-
tion sclerotherapy were used in 242 cases (88.6%) and 15
cases (5.5%), respectively. In patients who bled from gastric
varices, banding ligation and endoscopic variceal obturation
with N-butyl-2-cyanoacrylate (Histoacryl) were most fre-
quently used (32.3% and 30.3%, respectively).
Outcomes after acute UGI bleeding
Initial control of bleeding was achieved in 416 (86.8%)
of 479 episodes (Table 3). The median time from admission
to hemostasis was eight hours (range 0-504 hr). In the 63
cases (13.2%) where control of bleeding failed, the source of
bleeding was esophageal varices in 26 cases (41.3%), gastric
varices in nine (14.3%), and undefined in 27 (42.9%). The
rate of failure in initial hemostasis was significantly higher
in patients with variceal bleeding (35 of 372 patients, 9.4%)
than in those with nonvariceal bleeding (1 of 76, 1.3%; p=
0.011 between two groups). 
Five-day failure took place in 84 of the whole 479 (17.5%)
episodes as shown in Table 3, comprising 54 deaths and 15
Variceal bleeding, n (%)
Variceal Nonactive
Treatment
Bleeding from other 
sources, n (%)
Active Nonactive
Bleeding from undefined
sources, n (%)
Active Total
None 0 (0.0) 3 (1.2) 1 (3.8) 18 (36.0) 1 (3.2) 23 (4.8)
Endoscopic 5 (3.9) 29 (11.8) 13 (50.0) 11 (22.0) 0 (0.0) 58 (12.1)
Pharmacologic 2 (1.6) 24 (9.8) 0 (0.0) 7 (14.0) 7 (22.6) 40 (8.4)
Balloon tamponade alone 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (22.6) 7 (1.5)
Endoscopic+Pharmacologic 104 (81.9) 176 (71.8) 11 (42.3) 14 (28.0) 0 (0.0) 305 (63.7)
Endoscopic+Balloon tamponade 2 (1.6) 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.8)
Pharmacologic+Balloon tamponade 1 (0.8) 1 (0.4) 0 (0.0) 0 (0.0) 16 (51.6) 18 (3.8)
Endoscopic+Pharmacologic 13 (10.2) 10 (4.1) 1 (3.8) 0 (0.0) 0 (0.0) 24 (5.0)
+Balloon tamponade
Blood units
Within 24 hr 3.4±2.9 2.8±2.1 3.6±2.6 2.3±1.9 5.3±7.1 3.1±3.0
Total 5.8±5.9 4.2±3.8 4.9±3.7 4.0±5.5 6.0±7.2 4.8±4.9
Total 127 245 26 50 31 479
Table 2. Types of initial treatment for hemostasis in all patients according to the source of bleedingUpper Gastrointestinal Bleeding in Cirrhosis 639
cases of rebleeding and 15 failures in initial hemostasis of
patients who were still alive on day 5. The five-day failure
rate was not significantly different between patients with
variceal bleeding and patients with nonvariceal bleeding
(13.7% vs. 6.6%, p=0.09). The five-day failure rate was high
in patients with bleeding of undefined sources (28 of 31 cases,
90.3%), 27 of whom failed to control bleeds and 25 died. 
On the whole, 70 of 414 patients (16.9%) rebled within
six weeks of index bleeds, 16 (3.9%) within five days, 54
(13.4%) during days 6 to 42 (Table 3). The six-week rebleed-
ing rate was 18.4% (62 of 337 cases) for patients with variceal
Variceal 
bleeding
n (%)
Bleeding 
from 
other 
sources 
n (%)
Bleeding 
from unde-
fined 
sources 
n (%)
Total 
n (%)
Patients at risk 372 76 31 479
Failure to control bleeding
Day 1-5 35 (9.4) 1 (1.3) 27 (87.1) 63 (13.2)
Day 1-42 33 (8.9) 0 (0.0) 27 (87.1) 60 (12.5) 
Rebleeding*
Day 1-5 14 (4.2) 2 (2.7) 0 (0.0) 16 (3.8)
Day 6-42 48 (14.2) 5 (6.7) 1 (25.0) 54 (13.0)
Day 1-42 62 (18.4) 7 (9.3) 1 (25.0) 70 (16.8)
Deaths
Day 1-5 27 (7.3) 2 (2.6) 25 (80.6) 54 (11.3)
Uncontrolled bleeding 24 (6.5) 0 (0.0) 24 (77.4) 48 (10.0)
Uncontrolled rebleeding 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.2)
Other causes 2 (0.5) 2 (2.6) 1 (3.2) 5 (1.0)
Day 6-42 57 (15.3) 9 (11.8) 4 (12.9) 70 (14.6)
Uncontrolled bleeding 9 (2.4) 0 (0.0) 3 (9.7) 12 (2.5)
Uncontrolled rebleeding 12 (3.2) 1 (1.3) 0 (0.0) 13 (2.7) 
Liver failure 22 (5.9) 4 (5.3) 1 (3.2) 27 (5.6)
Other causes 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.2)
Unknown             13 (3.5) 4 (5.3) 0 (0.0) 17 (3.5)
Day 1-42 84 (22.6) 11 (14.5) 29 (93.5) 124 (25.9)
Child-Pugh class A 2 (3.0)
� 0 (0.0)
� - 2 (2.3)
�
class B 20 (12.3)
� 3 (9.4)
� 8 (88.9)t 31 (15.3)
�
class C 62 (43.1)
� 8 (33.3)
�21 (95.5)t 91 (47.9)
�
Rebleeders 20 (32.3)
� 2 (28.6)
� 1 (100.0)
�23 (32.9)
�
5-Day failure 51 (13.7) 5 (6.6) 28 (90.3) 84 (17.5)
Table 3. Treatment outcomes according to the source of bleeding
*, Patients with uncontrolled bleeding were not included in this analysis;
� , Proportion of patients dying in each subgroup according to the source
of bleeding and Child-Pugh class; 
� , Proportion of patients dying in the
group of patients with rebleeding according to the source of bleeding.
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Fig. 1. Cumulative incidence of rebleeding after hemostasis accord-
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bleedings, 9.3% (7 of 75) for patients with nonvariceal bleed-
ings and 25% (1 of 4) for patients with bleedings of unde-
fined source. There was no significant difference between
patients with variceal bleeding and patients with nonvariceal
bleeding (p=0.130, Fig. 1). Rebleeding was uncontrollable
in 14 of 70 patients (20%), including 13 of 62 variceal bleeds
and one of seven nonvariceal bleeds.
Overall, 124 of 479 patients (25.9%) died within six weeks
of index bleeds, 54 (11.3%) within five days, and 70 (14.6%)
during days 6 to 42 (Table 3). The six-week mortality rate
was 22.6% in patients with variceal bleeding, which was
not significantly different from that in patients with nonva-
riceal bleeding (14.5%, p=0.107, Fig. 2A). 
The mortality increased with the degree of hepatic dys-
function in patients with all known sources of bleeding (Table
3, Fig. 3A) as well as in cases with variceal bleeding (Fig.
3B). In the whole series (Table 3), failure to control initial
or recurrent bleeding was a main cause of death within six
weeks of hemorrhage and responsible for 74 of all 124 casu-
alties (59.7%), including 46 of 84 deaths due to variceal
bleeds (54.8%), for one of 11 deaths due to nonvariceal bleeds
(9.1%), and for 27 of 29 deaths due to bleeds of undefined
source (93.1%). In particular, the failure to control initial
bleeding was responsible for 88.9% (24 of 27 cases) and 96%
(24 of 25 cases) of all deaths within five days of bleeds from
varices and undefined sources, respectively, whereas it was
not related to early deaths due to nonvariceal bleeds. In con-
trast, the failure to control rebleeding accounted for 21.1%
(12 of 57 cases) and 11.1% (one of nine cases) of late deaths
that occurred after five days of variceal and nonvariceal bleed-
ing, respectively.
In multivariate analysis for 6-week mortality in patients
with variceal bleeding, baseline creatinine and AST level,
Child-Pugh class, portal vein thrombosis and active bleed-
ing from varices were the independent predictive factors for
survival (Table 4).
Prophylactic therapy for variceal rebleeding
Of 343 patients with successfully controlled variceal bleed-
ing, 321 (93.6%) received pharmacologic or endoscopic treat-
ments to prevent recurrent bleeding. In 22 patients, no pro-
phylactic therapy was performed. Pharmacologic prophy-
laxis was given to 194 patients (56.6%), commencing at
median four days (0-20 days) from admission. The main drug
prescribed was propranolol (184 of 194 cases, 95.4%), and
the median daily dose was 40 mg (10-240 mg).
Endoscopic prophylaxis was performed in 294 of 343 cases
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Variable Rating β OR 95% CI p
Creatinine mg/dL 0.160 1.174 1.096-1.257 <0.001
AST IU/L 0.000 1.000 1.000-1.001 <0.001
Child-Puch class 0=class A; 1=class B or C 2.249 9.477 2.332-38.504 0.002
Portal vein thrombosis 0=no; 1=yes 0.955 2.600 1.703-3.968 <0.001
Active bleeding 0=no; 1=yes 1.181 3.259 2.206-4.814 <0.001
Table 4. Prognostic factors for the 6-week mortality in patients with variceal bleeding by multivariate analysis
AST, aspartate aminotransferase; OR, odds ratio; CI, confidence interval.Upper Gastrointestinal Bleeding in Cirrhosis 641
(85.7%) with a total of 427 sessions. Endoscopic band liga-
tion was the most common technique applied (350 of 427
sessions, 82%), and at each session, median 4.2 bands were
used. Twenty-six sessions (6.1%) of endoscopic sclerothera-
py were performed in 23 cases using median 14.8 cc of etha-
nolamine olate per session. For gastric varices, 51 sessions of
Histoacryl injection were performed in 45 cases. At each ses-
sion, 2.7 cc of Histoacryl was injected. Variceal eradication
was achieved in 67 of 294 cases (22.8%) at 29±41 days
from the commencement of endoscopic prophylaxis.
Infectious complications
On admission, infections were proven in 64 of 479 patients
(13.4%); spontaneous bacterial peritonitis in 19 (4%), sepsis
in six (1.3%), pneumonia in four (0.8%), urinary tract infec-
tion in three (0.6%), cellulites in one (0.2%), and possible
infection in 31 (6.5%). Of 415 patients without signs of infec-
tion at admission, 199 (48%) were given prophylactic antibi-
otics. The most common agents prescribed were third-gener-
ation cephalosporins (79.9%), followed by quinolone (10.9%).
During hospitalization, a total of 37 patients (37 of 479,
7.7%) who had not shown signs of infection at admission,
were infected, including spontaneous bacterial peritonitis in
three (0.6%), sepsis in seven (1.5%), pneumonia in eight
(1.7%), urinary tract infection in two (0.4%), cholangitis
and renal abscess in one (0.2%), and possible infection in 16
(3.3%) cases. The incidence of infections during hospitaliza-
tion was not significantly different whether prophylactic
antibiotics were given or not (10.1% vs. 7.4%, respectively;
p=0.385).
Causative organisms were identified in 10 of 64 (15.6%)
patients with infections on admission and in 19 of 37 (51.4%)
patients with infections during hospitalization. Eight of 10
infections at admission (80%) were caused by Gram-nega-
tive bacilli. In contrast, 11 of 19 infections during hospital-
ization were caused by Gram-positive cocci, of which Staphy-
lococcus species were the most common organism (36.8%).
The incidence of infection was more frequent in patients
with Child-Pugh class C (58 of 190 cases, 30.5%) than those
with Child-Pugh class A or B (42 of 289, 14.5%; p<0.001).
DISCUSSION
This study included nine tertiary medical centers in dif-
ferent regions in Korea and enrolled all consecutive patients
with cirrhosis who had been admitted during a six-month
period for hematemesis and/or melena. Thus, the study, despite
being retrospective, can provide recent, representative data
about clinical features and treatment outcomes of cirrhotic
patients admitted for UGI bleeding in this country.
Several clinical features of the study are noteworthy. First,
esophagogastric variceal bleedings accounted for most (78%)
UGI bleeds in our cohort, a result somewhat higher than but
comparable with the proportions reported in some recent
studies (5, 9). Second, cirrhosis was related to alcohol abuse
in 60% of patients, including 40% with alcoholic cirrhosis,
which is appreciably higher than the usual proportion of alco-
hol abuse among the etiologies of cirrhosis in Korea (about
26%) (21). This result might be supported by several stud-
ies suggesting that ethanol consumption increases the risk
of variceal bleeding in patients with cirrhosis by increasing
hepatic vascular resistance, portal pressure, and variceal blood
flow (22, 23). Third, hepatocellular carcinoma was found in
as much as one-third of all patients, which was twice the
proportion of patients with hepatocellular carcinoma in the
recent study reported by D’Amico et al. (9). This might reflect
the geographic characteristics of the endemic area of hepatitis
B virus infection in Korea and be related to a relatively high-
er rate of failure to control bleeding in our series. Although
chronic hepatitis B virus carriers accounted for only 29%
(139 of 479) of all patients, they accounted for 71.6% (111
of 155) of patients with hepatocellular carcinoma.
This study showed a remarkable reduction in six-week
mortality after variceal hemorrhages when compared to that
in a pioneering study reported in 1981 by Graham et al. (2)
(from 42% to 23%), a result consistent with several recent
studies (5-9, 15). Actually, the proportion of patients with
Child-Pugh class C was significantly lower in this study
(38.7%) than in the study by Graham et al. (69.9%). How-
ever, this remarkable reduction in the mortality could be not-
ed when compared with other studies (mortality, 32-49%)
that included similar proportions of patients with Child-
Pugh class C (21-39%) with this study (3, 5). The most
prominent change was the reduction in five-day mortality,
which was 7.3% in the present study, whereas it was 23.5%
in the study by Graham et al. (2). By contrast, the mortality
after five days to six weeks of hemorrhage was similar between
the two studies (15.3% vs. 17.7%, respectively). This sug-
gests that a significant improvement in survival after variceal
bleeding in recent years is mainly attributable to the reduc-
tion in mortality during the early period of bleeding. This
has been achieved by the notable improvement in initial
hemostasis and prevention of early rebleeding with the devel-
opment of effective endoscopic and pharmacologic therapies
for controlling variceal bleeding. Indeed, in this study, ini-
tial hemostasis was achieved in 86.8% of cases in our series,
and rebleeding occurred in only 3.9% of patients within five
days of hemorrhage. However, if the cases with bleeding of
undefined source were counted as patients with variceal bleed-
ings, the five-day mortality and 6-week mortality in patients
with variceal bleeding increased to 12.9% and 28%, respec-
tively. Most previous studies included patients with variceal
bleeding that was identified by endoscopy. In our study, en-
doscopy could not be performed in many patients with cir-
rhosis and UGI bleeding because of hemodynamic instability.
Most of these patients with bleeding from undefined sources642 Y.S. Seo, Y.H. Kim, S.H. Ahn, et al.
might bleed from varices. Therefore, the actual mortality rate
in patients with cirrhosis variceal bleeding might be higher
than previously reported.
The rate of failure to control initial bleedings in this study
was higher for variceal than for nonvariceal hemorrhages
(9.4% vs. 1.3%), and this hemostatic failure eventually caused
more than 90% of casualties occurring within five days of
the variceal bleeds. Moreover, the early mortality of variceal
bleeding would be further increased if the hemorrhages from
undefined sources were included together, considering the
high proportion of variceal bleeding among all UGI bleeds
in our cohort. In this study, 87.1% of patients with undefined
source of bleeding failed in initial hemostasis and 80.6% died
within five days, which was prominently higher compared
with the five-day failure rate of 20% in a recent report by
D’Amico et al. (9). This big difference between the two stud-
ies might be partly explained by a far higher proportion of
patients with massive bleeding, liver failure or advanced hep-
atocellular carcinoma in our series.
Because variceal bleeding contributes to the considerable
mortality in patients with cirrhosis, a recent guideline rec-
ommends all patients with cirrhosis be screened for varices
and primary prophylaxis be given for those patients with
large varices (14). In the present study, only 8.9% of patients
without previous bleeding received primary prophylaxis.
This calls for much more efforts in providing primary pro-
phylaxis for variceal bleeding in the high-risk group.
Also, this study indicates that more effective secondary
prophylaxis is needed to prevent rebleeding. In the study,
11.3% of patients encountered rebleeding after five days of
initial bleeding and this is similar to the rebleeding rate of
10.6% in the Graham study 25 yr ago, which raises a ques-
tion about the effectiveness of current preventative measures.
In the present study, pharmacologic or endoscopic prophy-
laxis was executed in 94% of patients after achieving suc-
cessful initial hemostasis. In particular, endoscopic prophy-
laxis was commenced in 88% of cases, mainly using endo-
scopic variceal ligation (EVL); however, it was only in 22.8%
of cases that endoscopy was followed up until all varices were
eradicated. Although several studies reported that EVL was
effective for the prevention of rebleeding and could improve
survival (12, 24), it should be noted that the eradication of
varices was a prerequisite for achieving the goal in those clin-
ical trials. In this respect, the secondary endoscopic prophy-
laxis performed in the present study seems insufficient for
preventing rebleeding. Among 355 patients who survived
42 days from admission, the duration of follow-up was less
than 1 month in 93.8% of patients (333 of 355) and 60% of
these lost patients were alcoholics. The high rate of loss of
follow-up could be one reason for the low endoscopic eradica-
tion rate in our study. Similarly, nonselective beta-blockers
have been reported to reduce the incidence of rebleeding and
mortality in patients with prior variceal bleeding (25-27),
and in our series, they were prescribed in 57.9% of patients
after successful initial hemostasis. Usually, doses of beta-block-
er sufficient to diminish hepatic venous pressure gradient
(HVPG) to 12 mmHg or below, or to decrease heart rate by
more than 20% from baseline, are necessary to prevent rebleed-
ing effectively. Although it was not identified whether a suf-
ficient reduction in HVPG or heart rate was achieved after
the treatment with beta-blockers, the median maintenance
dose in our series was relatively lower than the dose in other
clinical trials (28, 29) and this might suggest an inadequacy
of secondary pharmacologic prophylaxis in our series. 
Several studies have suggested that the use of prophylac-
tic antibiotics decreased the incidence of infections and im-
proved the survival of cirrhotic patients with gastrointesti-
nal bleeding (13). Nowadays, it is recommended that antibi-
otic prophylaxis be instituted in patients presenting with
variceal bleeding at the time of admission (14). In this study,
prophylactic antibiotics were prescribed in 48% of 415 pati-
ents without signs of infection on admission, and infections
occurred in 8.7% of these patients. When considering the
incidence of infection was 25-50% in the preprophylactic
antibiotics era (5), the infection rate in our series appears to
be significantly decreased. Contrary to expectation, howev-
er, the antibiotic prophylaxis in the present study did not
substantially decrease the incidence of infection or the mor-
tality of patients. This result could possibly be explained by
selection bias: prophylactic antibiotics might have been pre-
scribed more frequently for patients with more serious clini-
cal conditions. The fact that this study was performed retro-
spectively and many cases of minor infectious events might
be missed during data collection could be another explana-
tion for this result. 
Despite these limitations, some interesting results were
found. The types of cultured organisms from the patients
who were infected during hospitalization significantly dif-
fered from those from the patients with infection at admis-
sion. Most infections that existed at admission were caused
by Gram-negative organisms, possibly derived from enteric
flora. In contrast, most infections that developed during hos-
pitalization were caused by Gram-positive organisms. This
difference might be accounted for by the fact that third-gen-
eration cephalosporins, most frequently used as prophylactic
antibiotics in this study, have a more powerful antibiotic
potency for Gram-negative organisms than for Gram-posi-
tive ones, and many invasive procedures such as endoscopic
therapy, intravenous puncture, or urinary catheter insertion
were performed during hospitalization.
In conclusion, the survival of patients with cirrhosis admitted
for UGI bleeding seems to be significantly improved in recent
years and this might be related to a striking reduction in five-
day mortality, owing to the development of endoscopic and
pharmacologic treatments for controlling variceal hemorrhage.
However, considering patients of undefined sources, the actual
mortality of patients with variceal bleeding may be somewhat
higher than previously reported data. Although secondaryUpper Gastrointestinal Bleeding in Cirrhosis 643
prophylaxis for variceal rebleeding was performed in most
patients, it seems insufficient to prevent rebleeding effective-
ly and more meticulous prophylactic treatment is needed.
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